Reckitt expands US manufacturing in $600 million investment
Subscribe to our free newsletter today to keep up to date with the latest manufacturing news.
Reckitt is expanding its manufacturing plans in North Carolina as part of a wider investment of up to $600 million across its US operations.
The consumer health company said it has increased investment in its Wilson, North Carolina, manufacturing facility, which is scheduled to open in the first half of 2027. The site will become Reckitt’s largest over-the-counter manufacturing facility in the US.
The additional funding will increase production capacity for Mucinex tablets and liquids and support higher volumes of Move Free products. Reckitt also plans to expand the physical footprint of the facility, leaving room to add more manufacturing capabilities as demand changes.
The investment is part of a wider multiyear program that includes a new North American commercial and research and development campus in New Jersey.
For manufacturers, the Wilson expansion is a notable part of the announcement. Reckitt is increasing its commitment to domestic production before the facility has begun commercial operations.
That suggests the company is taking a longer-term approach to capacity planning, particularly for consumer health products where demand can rise quickly and seasonal patterns can be difficult to predict.
The Wilson plant is expanding before production has started
Reckitt announced its Wilson manufacturing project in December 2024 after acquiring an existing pharmaceutical site of about 310,000 square feet.
At the time, the company said it planned to invest $200 million to establish the facility and manufacture Mucinex tablets and liquids for the US market. It also said the plant could later support other products, including Move Free and Biofreeze.
The latest announcement increases the scale of those plans.
Reckitt says the Wilson site will have additional production capacity for Mucinex tablets and liquids, as well as higher Move Free output. The larger footprint will also leave space for future manufacturing capabilities.
That flexibility could prove important. Pharmaceutical and consumer health manufacturers can face sharp changes in demand, particularly for cold and flu products.
When Reckitt first announced the facility, the company said demand for Mucinex had risen above historical pre-pandemic averages. It also pointed to less predictable patterns in respiratory illness, including demand outside traditional cold and flu seasons.
Building additional capacity closer to the end market can give manufacturers more options when demand changes. It can also reduce reliance on long international supply routes, although Reckitt has described the Wilson project more broadly in terms of supply resilience and access to health products.
The employment impact is also significant for Wilson County.
North Carolina officials said in 2024 that the project was expected to create 289 jobs. Roles were expected to include positions in manufacturing, engineering and quality functions. The state announcement recorded an investment of $145.59 million at that stage of the project.
Reckitt later announced a $200 million investment when it confirmed the acquisition of the site. The figures were published at different stages of the project and should be treated as separate disclosures.
More flexible capacity can help Reckitt respond to uneven demand
The Wilson expansion also shows how manufacturers are reassessing the role of spare capacity.
For many years, manufacturing investment often focused on efficiency and high plant use. That approach can reduce unit costs, but it can also leave less room to respond when demand changes quickly.
Consumer health products present a particular challenge because demand can be tied to illness patterns that are difficult to forecast.
A severe flu season can rapidly increase demand for cough and cold medicines. Respiratory illnesses can also rise outside normal seasonal periods.
Reckitt has said the expanded Wilson site will give it more manufacturing flexibility and room to add new capabilities as demand develops.
That makes the project relevant beyond the volume of Mucinex that the company intends to manufacture.
A plant designed to support several products and accommodate future production needs can give a manufacturer more options than a site built around one fixed process.
It also gives Reckitt more capacity inside its largest market. When announcing the Wilson project in 2024, the company said the facility would support a more resilient US supply chain.
The latest investment builds on that approach.
Rather than opening the original facility and adding capacity later, Reckitt is increasing the planned footprint before production begins.
Wilson is developing into a larger pharmaceutical manufacturing base
Reckitt is not the only health care manufacturer investing heavily in Wilson County.
Johnson & Johnson announced in October 2024 that it would invest more than $2 billion in a pharmaceutical manufacturing campus in Wilson. The company said the site would support production of biologic medicines and create 420 jobs.
Earlier that year, SCHOTT Pharma announced a $371 million production facility in Wilson County. The project was expected to create 401 jobs and manufacture drug containment and delivery systems for pharmaceutical and biotech companies.
Together, these projects are increasing the concentration of pharmaceutical and life sciences manufacturing in the area.
That could have wider effects on the local industrial base. Large manufacturing projects increase demand for skilled workers, technical education, suppliers, maintenance services and supporting infrastructure.
For Reckitt, being located in a growing pharmaceutical manufacturing region may become more relevant as the Wilson site develops.
The company’s immediate priority remains preparing the facility for its planned opening in the first half of 2027.
What stands out is that Reckitt is increasing the scale of the project before commercial production starts.
The original Wilson investment was intended to add US capacity for Mucinex and improve supply resilience. The latest plans broaden that role by increasing production, adding Move Free volumes and leaving more room for future manufacturing needs.
Combined with Reckitt’s planned New Jersey research and commercial campus, the investment also places product development and US manufacturing capacity within the same long-term program.
For manufacturing leaders, the Wilson project highlights a broader shift in capacity planning. New facilities are increasingly being designed to provide room for changing demand as well as higher output.
Source
